Vanguard Group
KBIO

Vanguard Group’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Vanguard Group’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-43,829
Closed – – 4239
2015
Q4 		$0 Sell
43,829
-600
-1% -$6.64K ﹤0.01% 4283
2015
Q3 		$85K Sell
44,429
-56,622
-56% -$149K ﹤0.01% 4110
2015
Q2 		$388K Buy
101,051
+11,913
+13% +$50.5K ﹤0.01% 3930
2015
Q1 		$349K Buy
89,138
+13,678
+18% +$61.3K ﹤0.01% 3911
2014
Q4 		$1.04M Buy
75,460
+8,736
+13% +$125K ﹤0.01% 3522
2014
Q3 		$827K Buy
66,724
+7,888
+13% +$109K ﹤0.01% 3563
2014
Q2 		$1.07M Buy
58,836
+10,448
+22% +$179K ﹤0.01% 3465
2014
Q1 		$1.05M Buy
48,388
+12,428
+35% +$360K ﹤0.01% 3444
2013
Q4 		$1.27M Buy
35,960
+4,745
+15% +$159K ﹤0.01% 3346
2013
Q3 		$1.13M Buy
31,215
+23,671
+314% +$1.08M ﹤0.01% 3334
2013
Q2 		$342K Buy
+7,544
New +$342K ﹤0.01% 3559

Other funds holding KBIO

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Vanguard Group's KBIO Position: Q1 2016 in Review

Vanguard Group sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q1 2016, closing a stake of 43,829 shares.

Vanguard Group first reported a position in KBIO in Q2 2013 and held it in 11 quarters. The position peaked at $1.27M in Q4 2013. 1 fund tracked by Wall St. Rank holds KBIO as of Q1 2016.

  • Vanguard Group reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q1 2016 after selling out during the quarter.
  • Vanguard Group sold 43,829 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q1 2016.
  • Vanguard Group first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 11 quarters.
  • Vanguard Group's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $1.27M in Q4 2013.
  • 1 fund tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q1 2016.

Based on Vanguard Group's 13F filing for Q1 2016, filed 13 May 2016.